The Pan American Health Organization (OPS) and the John Hopkins-joined NGO Jhpiego this week launched the Spanish version of application that facilitates the use of drugs to prevent the infection of HIV. Known by the name pre-exposure prophylaxis (PrEP), this method of prevention is the intake of antiretroviral drugs before contact with HIV. Drugs in this technique prevent the virus from entering the body.
Since 2010, new HIV cases have been around 120,000 years in Latin America and the Caribbean. Of these episodes of infection, 64% occur between gay men and men who have sex with other people, as well as sex workers, across people and other key groups and their sexual partners.
PrEP is one of the most effective resources available to prevent new infections in HIV. Since 2015, the World Health Organization (WHO) recommended that prepositional prophylaxis be offered as an additional option for people with a high risk of infection. The daily use of the indicated medicine reduces the risk of contracting the virus up to 90%.
Given the need for a practical advice on how to implement PrEP and start prophylaxis, WHO has developed the "Special PrEP" application, with a series of modules that can be accessed quickly and easily. smartphones and tablets. "Explaining access to PrEP can boost the reduction of new infections, especially among people who have a high risk of contracting HIV", says Massimo Ghidinelli, head of the OPS Unit for HIV, Hepatitis, Tuberculosis and Sexually Transmitted Infections.
"This measure, along with the use of other methods of prevention, including condoms, can help end AIDS (as a public health threat) by 2030."
The application of the Jhpiego NGO has five modules with information for doctors, advisers, pharmacists, HIV testing providers and users of PrEP. The software provides details of clinical issues, prophylaxis, criteria and anti-unions, drug regimes, usage, approach and advice. The program also spreads information on pharmaceutical issues, initiative and surveillance, key messages and frequently questions for people considering starting PrEP and those who already use it.
Preproductive prophylaxis is relatively new in the region of America. At present, only five countries offer the drug through their public policies: Bahamas, Barbados, Brazil, Canada and the United States. The Spanish version of the application – which was available in English since July 2018 – was announced at a meeting in Guatemala for innovation in Latin American efforts to end AIDS.